IFNAR

Vadimezan (DMXAA) is a vascular disrupting agent, a murine STING agonist, and an inducer of cytokines such as type I IFN. Vadimezan has antitumor activity and induces a rapid cessation of blood flow in tumors without affecting blood flow in normal tissues.

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12 23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.

Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).

CCCP (Carbonyl Cyanide m-Chlorophenylhydrazone) is an oxidative phosphorylation (OXPHOS) inhibitor and mitochondrial proton carrier uncoupler. CCCP inhibits the activation of STING and its downstream signaling molecules TBK1 and IRF3.

Ginsenoside-F3 has immunoenhancing activity by regulating production and gene expression of type 1, type 2 cytokines in murine spleen cells. Ginsenoside-F3 enhances the NF-kappaB DNA binding activity induced by ConA in murine spleen cells (10 μM).

Anifrolumab(MEDI-546) is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of type I interferon and is used for the prevention and treatment of systemic lupus erythematosus (SLE).

AX-024 hydrochloride (AX-024 HCl) is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.

Cridanimod (10-carboxymethyl-9-acridanone, CMA) is a potent STING agonist that directly binds to STING and triggers a strong antiviral response through the TBK1 IRF3 route.

RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.

Tilorone dihydrochloride, an orally active interferon inducer, exhibits both antineoplastic and anti-inflammatory actions.

IFN alpha-IFNAR-IN-1 hydrochloride is an inhibitor of the interaction between IFN-α and IFNAR, effectively inhibiting MVA-induced IFN-α responses by BM-pDCs with an IC50 of 2-8 μM.

Interferon receptor inducer-1 Used in the treatment of a disorder in which the induction of interferon is involved. is an interferon (IFN) receptor inducer.

CP-28888 (CP 28888-27) is an interferon inducer, a lipoamine with antitumor activity.

Alpinone 3-acetate showed anti-inflammatory effects and inhibited the inflammatory response in mouse ear edema models induced by 12-O-tetradecanophenol 13-acetate. Alpinone 3-acetate is a derivative of Alpinone. Alpinone is an active natural compound derived from sunflower with immunomodulatory and antiviral activities.

Peginterferon lambda-1a (BMS-914143) is a monoclonal antibody targeting IFNLR1, composed of IFNL1 conjugated to pegol [1].

Anti-Mouse IFN Gamma Antibody is a host Armenian Hamster-derived anti-mouse IFN gamma immunoglobulin G (IgG) inhibitor.

HEI3090 is an activator of the P2X7R receptor. This compound enhances the production of IL-18 by stimulating dendritic cells that express P2X7R, which in turn promotes the production of IFN-γ by natural killer cells and CD4T cells within tumors, triggering a sustained anti-tumor response. Additionally, HEI3090 can be used to improve the efficacy of αPD-1 therapy in non-small cell lung cancer (NSCLC).

Dazukibart is a humanized IgG1κ monoclonal antibody of murine origin, specifically targeting interferon beta 1 (IFNB1) [1].

Delmitide acetate (RDP58) is an orally active d-isomer decapeptide with potent anti-inflammatory properties, suppressing TNF-α, IFN-γ, and interleukin (IL)-12 production, while enhancing heme oxygenase 1 activity. It is utilized in research related to ulcerative colitis [1] [2].

MG-T-19 is an effective TIM-3 inhibitor that prevents interactions between TIM-3 and its ligands including PtdSer, CEACAM1, and Gal-9. Additionally, MG-T-19 enhances the production of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in peripheral blood mononuclear cells (PBMCs) from healthy donors and improves their ability to suppress the proliferation of Kasumi-1 cells (an acute myeloid leukemia cell line).

BMP-4, a heparin-binding peptide, exhibits anti-inflammatory and anti-chondrogenic properties. In murine chondrocytes and macrophages, it effectively mitigates inflammation and alleviates symptoms of various arthritides by dose-dependently suppressing the expression of inflammatory proteins such as iNOS, COX2, IFN, and IL6 through modulation of the iNOS-IFN-IL6 signaling pathway.

IFNα-IN-1 (AJ2-18) is an inhibitor of IFNα, capable of suppressing the production of IFN-α. It is applicable in inflammation research.